ストックスクリーナーアプリを入手
674.67
0.69%
4.34
前日終値:
$670.33
開ける：
$672.58
24時間の取引高:
200.22K
Relative Volume:
0.49
時価総額：
$41.30B
収益：
$2.58B
当期純損益:
$1.06B
株価収益率:
41.31
EPS:
16.33
ネットキャッシュフロー:
$-1.28B
1週間 パフォーマンス:
+14.01%
1か月 パフォーマンス:
+24.42%
6か月 パフォーマンス:
+3.03%
1年 パフォーマンス:
+30.76%
1日の値動き範囲:
$661.08
$676.12
1週間の範囲:
$590.78
$689.13
52週間の値動き範囲:
$475.65
$689.13
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
674.76 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.99 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.28 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.86 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beone Medicines Ltd Adr
|
296.90 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa
Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria
argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com Nigeria
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com
Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com
argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com
argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily
10 Stocks Analysts Are Upgrading Today - Insider Monkey
Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar
Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily
argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily
argenx ADR Earns Relative Strength Rating Upgrade - inkl
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa
Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily
Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India
Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa
Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India
Stifel maintains $780 target on argenx stock after FDA nod - Investing.com
Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily
Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa
Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com
Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com
TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India
TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com
Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa
Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India
argenx SE ADR to Host Earnings Call - ACCESS Newswire
Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com
Why This Biotech Tumbled For A Second Straight Day - Investor's Business Daily
Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar
Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com
H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts argenx stock price target to $720 - Investing.com
Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa
Argenx stock target lifted to $761 by TD Cowen, maintains buy - Investing.com India
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
0.44%
大文字化:
|
ボリューム (24 時間):